Carfilzomib-based strategies in transplant-eligible multiple myeloma: long-term follow-up of the phase 2 FORTE trial
In the phase 2 FORTE trial, transplant-eligible newly diagnosed multiple myeloma patients aged ≤65 years were randomized to (R1) carfilzomib-lenalidomide-dexamethasone followed by autologous stem cell transplantation (KRd-ASCT), twelve cycles of KRd (KRd12), or carfilzomib-cyclophosphamide-dexamethasone followed by ASCT (KCd-ASCT). Eligible patients were then randomized (R2) to maintenance with carfilzomib for 2 years plus lenalidomide until progression (KR) or lenalidomide alone until progression (R). With extended follow-up (median 99 months from R1 and 85 months from R2), KRd-ASCT significantly increased progression-free survival (PFS, median 98 months) versus KRd12 (median 70 months; HR 0.71, p=0.027) and KCd-ASCT (median 67 months; HR 0.66, p=0.006). A significant benefit in PFS2 was also observed versus both KRd12 (HR 0.65, p=0.02) and KCd-ASCT (HR 0.68, p=0.04) and in terms of overall survival (OS) versus KCd-ASCT (8-year OS: 76% vs 68%; HR 0.65, p=0.04). KR maintenance significantly improved PFS versus R (HR 0.67, p=0.02), with a time-dependent effect persisting up to two years after carfilzomib discontinuation; no differences in PFS2/OS were observed. KR significantly increased rate of measurable residual disease (MRD) conversion (sHR 0.47, p=0.03) during active treatment, and reduced MRD resurgence (sHR 0.53, p=0.001) versus R. Median duration of MRD negativity was 50.5 months in KR vs. 38 months in R arm. MRD-negative patients had significantly prolonged PFS with KR (HR 0.60, p=0.031); MRD-positive patients benefited from KR mainly during carfilzomib therapy (HR 0.46, p=0.05). The cumulative incidence of second primary malignancies was 6%. In conclusion, long-term follow-up confirms the high effectiveness of KRd-ASCT and KR maintenance. NCT02203643
Authors
- Mattia D’Agostino (ORCID: https://orcid.org/0000-0002-1711-6996)
- Massimo Gentile (ORCID: https://orcid.org/0000-0002-5256-0726)
- Michele Cea (ORCID: https://orcid.org/0000-0002-1530-6729)
- Francesca Fioritoni (ORCID: https://orcid.org/0000-0002-1274-8193)
- Stefania Oliva (ORCID: https://orcid.org/0000-0002-3084-180X)
- Sara Aquino (ORCID: https://orcid.org/0000-0002-8494-0627)
- Micol Quaresima (ORCID: https://orcid.org/0000-0001-9894-3872)
- Benedetto Bruno (ORCID: https://orcid.org/0000-0002-7299-6770)
- Delia Rota‐Scalabrini (ORCID: https://orcid.org/0000-0003-0744-6390)
- Pellegrino Musto (ORCID: https://orcid.org/0000-0003-3277-6594)
- Giuseppe Bertuglia (ORCID: https://orcid.org/0009-0009-3785-9824)
- Paolo de Fabritiis (ORCID: https://orcid.org/0000-0002-1835-0581)
- Stelvio Ballanti (ORCID: https://orcid.org/0000-0003-3549-711X)
- Paolo Corradini (ORCID: https://orcid.org/0000-0002-9186-1353)
- Elena Zamagni (ORCID: https://orcid.org/0000-0003-1422-7305)
- Francesca F. Patriarca (ORCID: https://orcid.org/0000-0002-9813-524X)
- Renato Zambello (ORCID: https://orcid.org/0000-0002-8799-5324)
- Sara Bringhen (ORCID: https://orcid.org/0000-0003-4539-6363)
- Francesca Fazio (ORCID: https://orcid.org/0000-0003-4187-8912)
- Angelo Belotti (ORCID: https://orcid.org/0000-0002-0617-3127)
- Nicola Giuliani (ORCID: https://orcid.org/0000-0003-3457-3774)
- Sonia Morè (ORCID: https://orcid.org/0009-0007-4398-7860)
- L. Paris
- Francesca Gay
- Mario Boccadoro
Institutions
- University of Parma (IT)
- University of Udine (IT)
- University of Padua (IT)
- University of Milan (IT)
- Policlinico Umberto I (IT)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Azienda Ospedaliera di Perugia (IT)
- Azienda Sanitaria Unità Locale di Reggio Emilia (IT)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Ospedale Papa Giovanni XXIII (IT)
- Ospedali Riuniti di Ancona (IT)
- Ospedale Annunziata di Cosenza (IT)
- Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT)
- St. Eugenio Hospital (IT)
- Ospedale Policlinico San Martino (IT)
- Azienda USL di Pescara (IT)
- Candiolo Cancer Institute (IT)
- University of Turin (IT)
- University of Bari Aldo Moro (IT)
- University of Genoa (IT)
Publication Details
- Journal
- Blood
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1182/blood.2026035635
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00